Human Genome Sciences Inc. (HGSI) reported first quarter financial results Wednesday after the close of trade, posting its first ever product-related sales and profits that even beat Wall Street's estimates. To what does Human Genome owe its success? Why to Anthrax, of course.
Human Genome earned $129.8 million, or 85 cents per share, compared with a loss of $52.7 million, or 39 cents per share, during the same period a year prior. Revenue surged to $177.3 million from only $12.3 million. This beat the average analysts estimate polled by Thomson Reuters of profit of 54 cents per share on revenue of $150.4 million.
While revenue in the first quarter also included payments from partnerships for reaching milestones -- as it usually does for HGS -- this time nearly 87 percent of it stemmed from its AbThrax anthrax treatment sales to the federal government. The biotech company is under contract to deliver 27,000 doses of the drug for the U.S. Strategic National Stockpile, which the government would use in the event of a national emergency like a flu outbreak, terrorist attacks or earthquakes that are severe enough to cause local supplies to run out.
The stock is surging 35 percent today, but investors may be jumping ahead of themselves as the positive numbers are probably temporary. HGS was under contract this quarter, but it delivered most of the doses and expects a much smaller payment in the next quarter. HGS is trying to get another contract from the government, but so far, no specific word on that.
Meanwhile, the company is continuing to develop the drugs that should be the main growth drivers going forward: Hepatitis C drug Albuferon, lupus drug LymphoStat-B, and Syncria for type-2 diabetes, all in different stages of Phase 3 trials:
- Albuferon, which previously disappointed investors by not performing as well as hoped in trials despite achieving efficacy comparable to rivals with half the injections, could be the first HGS product approved by the FDA, perhaps by the second half of 2010.
- Analysts are also concerned about LymphoStat-B as data from clinical trials is still unknown and will be released this July and November. GlaxoSmithKline (GSK) paid
$1.6 as per agreements forthe LymphoStat-B drug.
- Syncria received a $9 million payment from GSK for achieving the milestone of Phase 3 initiation.